Anirban Maitra

Dr. Anirban Maitra

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2017 in Science
Verified
Journal Article
Closed access
PDF file
LGLeore T. Geller
Leore T. Geller
MBMichal Barzily-Rokni
Michal Barzily-Rokni
TDTal Danino
Tal Danino
OJOliver H. Jonas
Oliver H. Jonas
NSNoam Shental
Noam Shental
RSRavid Straussman
Ravid Straussman
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2′,2′-difluorodeoxycytidine) into its inactive form, 2′,2′-difluorodeoxyuridine. Metabolism was dependent on the expression of a long isoform of the bacterial enzyme cytidine deaminase (CDDL), seen primarily in Gammaproteobacteria. In a colon cancer mouse model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of these tumors. Consistent with this possibility, we found that of the 113 human PDACs that were tested, 86 (76%) were positive for bacteria, mainly Gammaproteobacteria.

13 April 2023 in Cell
Verified
Journal Article
Open access
CHChristopher J. Halbrook
Christopher J. Halbrook
CLCostas A. Lyssiotis
Costas A. Lyssiotis
MMMarina Pasca di Magliano
Marina Pasca di Magliano
AMAnirban Maitra
Anirban Maitra
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant efforts have largely defined major genetic factors driving PDAC pathogenesis and progression. Pancreatic tumors are characterized by a complex microenvironment that orchestrates metabolic alterations and supports a milieu of interactions among various cell types within this niche. In this review, we highlight the foundational studies that have driven our understanding of these processes. We further discuss the recent technological advances that continue to expand our understanding of PDAC complexity. We posit that the clinical translation of these research endeavors will enhance the currently dismal survival rate of this recalcitrant disease.

11 May 2020 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
AHAbdel N. Hosein
Abdel N. Hosein
Rolf BrekkenRolf Brekken
Rolf Brekken
AMAnirban Maitra
Anirban Maitra

19 April 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
MMMayela Mendt
Mayela Mendt
SKSushrut Kamerkar
Sushrut Kamerkar
HSHikaru Sugimoto
Hikaru Sugimoto
KMKathleen M. McAndrews
Kathleen M. McAndrews
CWChia-Chin Wu
Chia-Chin Wu
RKRaghu Kalluri
Raghu Kalluri
Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.

29 May 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YCYanshuo Chu
Yanshuo Chu
EDEnyu Dai
Enyu Dai
YLYating Li
Yating Li
GHGuangchun Han
Guangchun Han
GPGuangsheng Pei
Guangsheng Pei
LWLinghua Wang
Linghua Wang

28 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
VCVidhi Chandra
Vidhi Chandra
ESErick Riquelme Sanchez
Erick Riquelme Sanchez
PDPrasanta Dutta
Prasanta Dutta
PQPompeyo R. Quesada
Pompeyo R. Quesada
FMFlorencia McAllister
Florencia McAllister
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with an immunosuppressive microenvironment that is resistant to most therapies. IL17 is involved in pancreatic tumorigenesis, but its role in invasive PDAC is undetermined. We hypothesized that IL17 triggers and sustains PDAC immunosuppression. We inhibited IL17/IL17RA signaling using pharmacological and genetic strategies alongside mass cytometry and multiplex immunofluorescence techniques. We uncovered that IL17 recruits neutrophils, triggers neutrophil extracellular traps (NETs), and excludes cytotoxic CD8 T cells from tumors. Additionally, IL17 blockade increases immune checkpoint blockade (PD-1, CTLA4) sensitivity. Inhibition of neutrophils or Padi4-dependent NETosis phenocopies IL17 neutralization. NMR spectroscopy revealed changes in tumor lactate as a potential early biomarker for IL17/PD-1 combination efficacy. Higher expression of IL17 and PADI4 in human PDAC corresponds with poorer prognosis, and the serum of patients with PDAC has higher potential for NETosis. Clinical studies with IL17 and checkpoint blockade represent a novel combinatorial therapy with potential efficacy for this lethal disease.